Author

Arshan Nasir

Moderna Therapeutics (United States)ORCID 0000-0001-7200-0788Unclaimed ORCID profile · follow to get notified of new preprints

Additional preprints under this name without ORCID

Arshan Nasir1 paper

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:mouse· 2 Assay:bulk RNA-seq· 1 Research Focus:host-pathogen & immune response· 1 Approach:statistical model· 1 Organism:virus· 1

Frequent Co-Authors

Andrea Carfı́iD· 3 shared Daniela Montes Berrueta· 3 shared Darin K. EdwardsiD· 3 shared Diana Wing LeeiD· 3 shared Tessa SpeideliD· 3 shared Yadunanda BudigiiD· 3 shared Amy Gorrie· 2 shared Hardik JaniiD· 2 shared

Activity by Year

2025-2026 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersImmunology

Andrea Carfı́ORCID

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

ImmunologyJournal of VirologyPeer-reviewedApr 27, 2026

Predictive Modeling of Immune Escape and Antigenic Grouping of SARS-CoV-2 Variants

Arshan Nasir, Diana Wing Lee, Laura E. Avena…·Darin K. Edwards

The paper develops a risk calculator to predict immune escape of SARS-CoV-2 variants and group antigenically related variants to guide vaccine strain selection.

5 citationstop 1%

virusbulk RNA-seq

𝕏 PostBluesky

ImmunologybioRxivPreprintSep 16, 2025

mRNA-1273.251 and mRNA-1283.251 vaccines expressing SARS-CoV-2 variant LP.8.1 antigens broadly neutralize contemporary JN.1-lineage viruses

Arshan Nasir, Diana Wing Lee, Ziqiu Wang…·Alec W. Freyn

This study develops and evaluates two mRNA vaccines targeting the LP.8.1 variant of SARS-CoV-2, showing broad neutralization against JN.1-lineage subvariants.

1 citation

mouseexperimental assay

𝕏 PostBluesky

ImmunologyVaccinePeer-reviewedMar 7, 2025

mRNA-1273 vaccines adapted to JN.1 or KP.2 elicit cross-neutralizing responses against the JN.1 sublineages of SARS-CoV-2 in mice

Diana Wing Lee, Arshan Nasir, Sayda M. Elbashir…·Yadunanda Budigi

This study evaluates JN.1 and KP.2 mRNA vaccines in mice, showing they elicit strong neutralizing antibodies against JN.1 subvariants and cross-neutralize KP.3, LA.2, and XEC.

16 citationstop 1%

mouseexperimental assay

𝕏 PostBluesky